Spyre Therapeutics breaks higher on positive data from ulcerative colitis drug

Spyre Therapeutics Inc. SYRE shares are up on Monday following the announcement of positive results from the Phase 2 SKYLINE ...
InvestorsHub on MSN

Spyre Therapeutics shares jump after positive ulcerative colitis trial data

Spyre Therapeutics (NASDAQ:SYRE) shares climbed 25% on Monday after the company reported that its investigational therapy ...
clinicaladvisor.com

American Gastroenterological Association Releases First “Living” Guideline for Moderate-to-Severe Ulcerative Colitis

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
Seeking Alpha

Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

-PK/PD confirm results seen in healthy volunteer studies, with median RO >99% and saturation achieved early and sustained at week 12- WALTHAM, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Morphic ...
Becker's ASC

Entyvio improves moderate-to-severe ulcerative colitis, Crohn’s

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel ...
Morningstar

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory ...
Healio

‘Early, effective’ biologics may slash progression risk in ulcerative colitis fivefold

Biologic therapy within a year of diagnosis could decrease risk for disease progression among patients with ulcerative ...
Morningstar

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...